Rockwell Medical, Inc. (RMTI)

Rockwell Medical's stock (RMTI) has experienced several notable events in the past six months. In Q1 2026, net sales fell short of expectations, but earnings beat forecasts, leading to a share price decline. In Q4 2025, net sales declined year-over-year, but the company achieved profitability on an Adjusted EBITDA basis for the second consecutive year. Between May 7, 2025, and May 6, 2026, the share price declined by 27.68%.

Rockwell Medical experiences some demand seasonality, with slightly negative adjusted EBITDA in the first quarter due to seasonal items related to payroll tax and other public company expenses. The company observed sequential growth each month during the first quarter of 2026 in gross margin, gross profit, adjusted EBITDA, and net income, with expectations for this trend to continue. The overall market for hemodialysis concentrates is projected to grow at a compound annual growth rate of 4-6% from $450 million in 2024 to $560 million by 2028.

Rockwell Medical, Inc. (RMTI) is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers globally. The company's primary products are hemodialysis concentrates, essential for hemodialysis patients with end-stage kidney disease. Its product portfolio includes CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, Dri-Sate acid concentrate mixer, RenalPure acid concentrate, RenalPure bicarbonate concentrate, SteriLyte bicarbonate concentrate, bicarbonate cartridges, dry acid concentrate mixer and ancillary products. The company previously commercialized Triferic (ferric pyrophosphate citrate), but U.S. commercialization has been discontinued, while international partnerships remain.

Rockwell Medical serves approximately 300 customers across the United States, including major dialysis providers like Fresenius Medical Care and DaVita. The company operates manufacturing and distribution facilities in Iowa, Michigan, Minnesota, South Carolina, and Texas. Internationally, Rockwell Medical distributes its hemodialysis concentrates to over 30 countries across North America, South America, Europe, Africa, and Asia.

Rockwell Medical has a strong brand reputation due to its commitment to employees and the quality of its products and services. The company has been certified as a "Great Place to Work®" for four consecutive years and was named among Fortune's Best Workplaces in Manufacturing & Production™ in both 2024 and 2025. The company emphasizes its mission to provide dialysis clinics and patients with high-quality products and exceptional customer service, building a long-standing reputation for reliability, quality, and excellent customer care.

Rockwell Medical, Inc. has 39 institutional owners and shareholders holding a total of 3,680,652 shares, representing 9.34% of institutional shares. Major institutional owners include Vanguard Group Inc., Renaissance Technologies Llc, and Geode Capital Management, Llc. Insider ownership of Rockwell Medical is reported at 20.9%, representing 8.23 million shares.